{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:42:45Z","timestamp":1787794965389,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China"},{"name":"Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The Realgar-Indigo Naturalis formula (RIF) is a proprietary Chinese medicine, which is one of the important drugs in the treatment of pediatric acute promyelocytic leukemia (APL). However, the dose of RIF in clinical application is not uniform and the long-term effectiveness and safety of combining RIF with all-trans retinoic acid (ATRA) in a larger population of pediatric APL patients remains undocumented. We conducted a multicenter single-arm clinical trial (ChiCTR-OIC-16010014) in China. Individuals newly diagnosed with APL were treated with CCCG-APL-2017 protocol which is based on RIF and ATRA in consolidation. The event-free survival (EFS) and overall survival (OS) outcomes were evaluated. We recruited 200 patients diagnosed with APL. The six-year OS rate was 100% in the low-risk (LR) group and 97.6% in the high-risk (HR) group. The six-year EFS rate was 98.3% in the LR group and 97.6% in the HR group. Plasma levels of arsenic remained stable after the administration of RIF at a dosage of 60\u2009mg\/kg\/d for seven days and returned to baseline levels within fourteen days after discontinuation of RIF administration, which is consistent with a concentration of 135\u2009mg\/d\/kg. Furthermore, controlling white blood cells (WBC) to maintain levels at or below 30\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L during induction therapy can decrease the incidence of induced differentiation syndrome (DS) or alleviate its symptoms. Our study demonstrated that the CCCG-APL-2017 protocol, which combines RIF with ATRA, is both effective and safe in treating children with APL.<\/jats:p>","DOI":"10.1038\/s41392-025-02353-1","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T23:01:46Z","timestamp":1755817306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A multicenter single-arm clinical study of Chinese children\u2019s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol"],"prefix":"10.1038","volume":"10","author":[{"given":"Lixian","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuquan","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaizhi","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-3106","authenticated-orcid":false,"given":"Xiuli","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"2353_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041582","volume":"14","author":"D R\u00e9rolle","year":"2024","unstructured":"R\u00e9rolle, D., Wu, H. C. & de Th\u00e9, H. Acute promyelocytic leukemia, retinoic acid, and arsenic: A tale of dualities. Cold Spring Harb. Perspect. Med 14, a041582 (2024).","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"2353_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-024-00928-8","volume":"19","author":"J Chen","year":"2024","unstructured":"Chen, J. & Ding, Z. Natural products as potential drug treatments for acute promyelocytic leukemia. Chin. Med. 19, 57 (2024).","journal-title":"Chin. Med."},{"key":"2353_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/ejh.12194","volume":"91","author":"Y Cheng","year":"2013","unstructured":"Cheng, Y. et al. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. Eur. J. Haematol. 91, 483\u2013489 (2013).","journal-title":"Eur. J. Haematol."},{"key":"2353_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","volume":"88","author":"GQ Chen","year":"1996","unstructured":"Chen, G. Q. et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha\/PML proteins. Blood 88, 1052\u20131061 (1996).","journal-title":"Blood"},{"key":"2353_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","volume":"72","author":"ME Huang","year":"1988","unstructured":"Huang, M. E. et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567\u2013572 (1988).","journal-title":"Blood"},{"key":"2353_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","volume":"8","author":"MA Kutny","year":"2022","unstructured":"Kutny, M. A. et al. Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: A report from the children\u2019s oncology group AAML1331 Trial. JAMA Oncol. 8, 79\u201387 (2022).","journal-title":"JAMA Oncol."},{"key":"2353_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2019000760","volume":"134","author":"HH Zhu","year":"2019","unstructured":"Zhu, H. H., Hu, J., Lo-Coco, F. & Jin, J. The simpler, the better: Oral arsenic for acute promyelocytic leukemia. Blood 134, 597\u2013605 (2019).","journal-title":"Blood"},{"key":"2353_CR8","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.3390\/cancers15194767","volume":"15","author":"AC Woods","year":"2023","unstructured":"Woods, A. C. & Norsworthy, K. J. Differentiation syndrome in acute leukemia: APL and beyond. Cancers (Basel) 15, 4767 (2023).","journal-title":"Cancers (Basel)"},{"key":"2353_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjh.16151","volume":"187","author":"M Stahl","year":"2019","unstructured":"Stahl, M. & Tallman, M. S. Differentiation syndrome in acute promyelocytic leukaemia. Br. J. Haematol. 187, 157\u2013162 (2019).","journal-title":"Br. J. Haematol."},{"key":"2353_CR10","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1073\/pnas.0712365105","volume":"105","author":"L Wang","year":"2008","unstructured":"Wang, L. et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 105, 4826\u20134831 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2353_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00949-w","volume":"13","author":"D-P Huang","year":"2023","unstructured":"Huang, D.-P. et al. Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group. Blood Cancer J. 13, 178 (2023).","journal-title":"Blood Cancer J."},{"key":"2353_CR12","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1200\/JCO.2013.48.8312","volume":"31","author":"HH Zhu","year":"2013","unstructured":"Zhu, H. H. et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J. Clin. Oncol. 31, 4215\u20134221 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2353_CR13","doi-asserted-by":"publisher","first-page":"8314176","DOI":"10.1155\/2022\/8314176","volume":"2022","author":"S Luo","year":"2022","unstructured":"Luo, S. et al. Oral realgar-indigo naturalis formula treatment for acute promyelocytic leukemia in children: A randomized, control clinical trial. Evid. Based Complement Altern. Med. 2022, 8314176 (2022).","journal-title":"Evid. Based Complement Altern. Med."},{"key":"2353_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.leukres.2015.09.007","volume":"39","author":"H Jiang","year":"2015","unstructured":"Jiang, H. et al. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. Leuk. Res 39, 1319\u20131324 (2015).","journal-title":"Leuk. Res"},{"key":"2353_CR15","first-page":"154","volume":"14","author":"Q Huang","year":"2022","unstructured":"Huang, Q. et al. Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms. Chin. Herb. Med 14, 154\u2013165 (2022).","journal-title":"Chin. Herb. Med"},{"key":"2353_CR16","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1200\/JCO.20.03096","volume":"39","author":"H Zheng","year":"2021","unstructured":"Zheng, H. et al. Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study. J. Clin. Oncol. 39, 3161\u20133170 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2353_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00280-022-04449-9","volume":"90","author":"LH Liao","year":"2022","unstructured":"Liao, L. H. et al. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia. Cancer Chemother. Pharm. 90, 45\u201352 (2022).","journal-title":"Cancer Chemother. Pharm."},{"key":"2353_CR18","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/DDDT.S305244","volume":"15","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Population pharmacokinetics and safety of oral tetra-arsenic tetra-sulfide formula in pediatric acute promyelocytic leukemia. Drug Des. Devel Ther. 15, 1633\u20131640 (2021).","journal-title":"Drug Des. Devel Ther."},{"key":"2353_CR19","doi-asserted-by":"publisher","first-page":"20230847","DOI":"10.1515\/med-2023-0847","volume":"18","author":"L Chang","year":"2023","unstructured":"Chang, L. et al. Establishing a novel Fanconi anemia signaling pathway-associated prognostic model and tumor clustering for pediatric acute myeloid leukemia patients. Open Med (Wars.) 18, 20230847 (2023).","journal-title":"Open Med (Wars.)"},{"key":"2353_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-023-01730-5","volume":"16","author":"L Chang","year":"2023","unstructured":"Chang, L. et al. Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia. BMC Med Genomics 16, 290 (2023).","journal-title":"BMC Med Genomics"},{"key":"2353_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/med4.86","volume":"2","author":"R Mohamed","year":"2024","unstructured":"Mohamed, R. et al. Development of a local nomogram-based scoring system for predicting overall survival in idiopathic pulmonary fibrosis: A rural appalachian experience. Med Adv. 2, 336\u2013348 (2024).","journal-title":"Med Adv."},{"key":"2353_CR22","first-page":"3345","volume":"89","author":"G-Q Chen","year":"1997","unstructured":"Chen, G.-Q. et al. Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL): I. As2O3 Exerts Dose-Dependent Dual Effects on APL Cells. Blood 89, 3345\u20133353 (1997).","journal-title":"Blood"},{"key":"2353_CR23","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/ajh.25271","volume":"93","author":"MH Yang","year":"2018","unstructured":"Yang, M. H. et al. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study. Am. J. Hematol. 93, 1467\u20131473 (2018).","journal-title":"Am. J. Hematol."},{"key":"2353_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bjh.16364","volume":"188","author":"E Garcia Spezza","year":"2020","unstructured":"Garcia Spezza, E. et al. Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France. Br. J. Haematol. 188, 170\u2013173 (2020).","journal-title":"Br. J. Haematol."},{"key":"2353_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.clml.2021.12.007","volume":"22","author":"RR Deka","year":"2022","unstructured":"Deka, R. R. et al. FLT3-ITD mutation does not influence survival outcome in adult acute promyelocytic leukemia patients treated with ATO and ATRA-based therapeutic regimen: Experience From a North Indian Tertiary Care Centre\u2019. Clin. Lymphoma Myeloma Leuk. 22, 416\u2013423 (2022).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2353_CR26","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2005-10-4006","volume":"107","author":"E Estey","year":"2006","unstructured":"Estey, E. et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107, 3469\u20133473 (2006).","journal-title":"Blood"},{"key":"2353_CR27","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.3390\/jcm9103342","volume":"9","author":"L Gasparovic","year":"2020","unstructured":"Gasparovic, L., Weiler, S., Higi, L. & Burden, A. M. Incidence of differentiation syndrome associated with treatment regimens in acute myeloid leukemia: A systematic review of the literature. J. Clin. Med 9, 3342 (2020).","journal-title":"J. Clin. Med"},{"key":"2353_CR28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2009","unstructured":"Montesinos, P. et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113, 775\u2013783 (2009).","journal-title":"Blood"},{"key":"2353_CR29","first-page":"90","volume":"95","author":"MS Tallman","year":"2000","unstructured":"Tallman, M. S. et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95, 90\u201395 (2000).","journal-title":"Blood"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02353-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02353-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02353-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:15:32Z","timestamp":1757409332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02353-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2353"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02353-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}